Oxiperomide

This classification denotes an antiparkinsonian agent with the molecular formula C20H23N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WRO75M6RW2, chemically known as 2h-benzimidazol-2-one, 1,3-dihydro-1-(1-(2-phenoxyethyl)-4-piperidinyl)- but generally known as oxiperomide, which bears US NIH Compound Identifier 68634. European Medicines Agency schedules Oxiperomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09534MIG. The term OXIPEROMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). OXIPEROMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxiperomide under HS 29333999 and SITC 51574. As of Q4 2014, OXIPEROMIDE remains the US FDA Preferred Term for this commodity. Oxiperomide bears US NLM identifiers UMLS ID C0069771 and NCI Concept Code C66270. SMILES: O(CCN1CCC(N2C3C([NH]C2=O)CCCC3)CC1)C1CCCCC1.